Succinyl Curcumin Conjugated Chitosan Polymer-Prodrug Nanomicelles: A Potential Treatment for Type-II Diabetes in Diabetic Balb/C Mice

Authors

  • Rahaman Sk Mosiur Laboratory of Nanomedicine, Division of Pharmaceutical Biotechnology, Department of Pharmaceutical Technology, Jadavpur University, Kolkata 700032, West Bengal, India
  • Gouranga Dutta Department of Pharmaceutics, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur 603203, Tamilnadu, India
  • Ranu Biswas Department of Pharmaceutical Technology, Jadavpur University, Kolkata 700032, West Bengal, India
  • Abimanyu Sugumaran Department of Pharmaceutical Sciences, Assam University ( A Central University), Silchar, India
  • Mohamed M. Salem College of Medicine, Huazhong University of Science and Technology, China.
  • Mohammed Gamal Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Beni-Suef University, Alshaheed Shehata Ahmad Hegazy St., 62514, Beni-Suef, Egypt.
  • Mohamed AbdElrahman Clinical Pharmacy Department, College of Pharmacy, Al-Mustaqbal University, Babylon, 51001, Iraq
  • Mounir M. Salem-Bekhit Department of Pharmaceutics, College of Pharmacy, King Saud University, PO Box 2457, Riyadh 11451, Saudi Arabia

DOI:

https://doi.org/10.17344/acsi.2024.8658

Abstract

Diabetes mellitus is a chronic metabolic disorder marked by elevated blood sugar levels, leading to organ dysfunction. Curcumin, derived from turmeric, exhibits promise in managing type II diabetes. Nanomicelles were created by conjugating curcumin with chitosan through succinic anhydride. Succinyl-curcumin, the resultant compound, was esterified with chitosan to form a polymer prodrug conjugate. Nanomicelles, formed via dialysis, were spherical with a hydrodynamic size of 49.37 nm. In vitro release studies revealed 97% curcumin release at pH 5 in 7 days. A 21-day experiment on diabetic mice compared nanomicelles, standard drug, and free curcumin's impact on fasting blood glucose. The study showcased gradual, controlled curcumin release from nanomicelles, suggesting their potential in type II diabetes treatment.

Downloads

Published

10.06.2024

Issue

Vol. 71 No. 2 (2024): Acsi

Section

Biomedical applications

License

Copyright (c) 2024 Rahaman Sk Mosiur, Gouranga Dutta, Ranu Biswas, Abimanyu Sugumaran, Mohamed M. Salem, Mohammed Gamal, Mohamed AbdElrahman, Mounir M. Salem-Bekhit

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Except where otherwise noted, articles in this journal are published under the Creative Commons Attribution 4.0 International License